Menu
 

Search abstracts


Outcome analysis of liraglutide versus other antidiabetic medications in type 2 diabetes

  • At: 2018 FIP Congress in Glasgow (Scotland)
  • Type: Poster
  • By: CHANG, Hsiu-Mei (Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Department of Pharmacy)
  • Co-author(s): Hsiu-Mei Chang: Department of Pharmacy, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Jiun-Shiuan He: Department of Management, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Kun-Der Lin: Division of Endocrinology & Metabolism, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Yen-Huei (Tony) Tarn: School of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
    Ying-Chi Lin: School of Pharmacy, Kaohsiung Medical University, Kaohsiung City, Taiwan, Province of China
  • Abstract:

    Background

    Liraglutide is a glucagon-like peptide-1(GLP-1) receptor agonist approved for the treatment of type-2 diabetes mellitus (T2DM). Despite of high cost, liraglutide gradually become popular in our hospital since its availability in 2012.

    Methods

    A retrospective cohort study in adult patients diagnosed with T2DM was conducted using database

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 13 May 2019

FIP Congresses